References
- AttardAOlofinjanaOCorneliusVCurtisVTaylorDPaliperidone palmitate long-acting injection – prospective year-long follow-up of use in clinical practiceActa Psychiatr Scand20141301465124117209
- TaylorDOlofinjanaOLong-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalizationInt Clin Psychopharmacol201429422923424419004
- CordinerMShajahanPMcAvoySBashirMTaylorMEffectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoateTher Adv Psychopharmacol201661223226913175
- WhaleRPereiraMCuthbertSFialhoREffectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatmentJ Clin Psychopharmacol201535559159526267419
- TaylorDMSparshattAO’HaganMDzahiniOPaliperidone palmitate: factors predicting continuation with treatment at 2 yearsEur Neuropsychopharmacol201626122011201727743760
- BressingtonDStockJHulbertSMacInnesDA retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization ratesInt Clin Psychopharmacol201530423023625882381
- Mesones-PeralJEGurillo-MuñozPSánchez-SiciliaMPMillerAGriñant-FernándezAHospitalizaciones y análisis económico en pacientes psicóticos con palmitato de paliperidona de larga duración [Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection]Rev Psiquiatr Salud Ment20171013337 Spanish27053545
- NikolićNPageNAkramAKhanMThe impact of paliperidone palmitate long-acting injection on hospital admissions in a mental health settingInt Clin Psychopharmacol20173229510227898432
- TaylorDMSparshattAO’HaganMDzahiniOEffect of paliperidone palmitate on hospitalisation in a naturalistic cohort – a four-year mirror image studyEur Psychiatry201637434827447102
- VincentPDDemersM-FDoyon-KempVDuchesneauJHalmeAMassonVOne year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in CanadaSchizophr Res20171859610028119036
- ZhangFSiTChiouCFEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaNeuropsychiatr Dis Treat20151165766825792835
- AlphsLMaoLRodriguezSCHulihanJStarrHLDesign and rationale of the paliperidone palmitate research in demonstrating effectiveness (PRIDE) studyJ Clin Psychiatry201475121388139325375367
- AlphsLBensonCCheshire-KinneyKReal-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophreniaJ Clin Psychiatry201576555456125938474
- AlphsLMaoLLynn StarrHBensonCA pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophreniaSchizophr Res20161702–325926426742509
- EnglandNHSMental Health Clustering Booklet (V4.0)2015 Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/379574/S118_Annex_7C_NTCN1516.pdfAccessed December 13, 2017
- JacobsRPayment by results for mental health services: economic considerations of case-mix fundingAdv Psychiatr Treat201420315516410.1192/apt.bp.113.011312
- SpeakBHayPThe Utility of the Mental Health Clustering Tool (MHCT) as a Generic Outcome Measure for the Payment by Results Quality and Outcomes Framework in Working Age and Older Adult Mental Health Services: Final Report Care Pathways and Packages Project Consortium2012 Available from: http://webarchive.nationalarchives.gov.uk/20120830110210/http://www.cppconsortium.nhs.uk/admin/files/1345023760Theutility of the MHCT as a generic outcome measure for the PbR quality and outcomes framework for working age and older adult mental health.pdfAccessed May 10, 2017
- GharabawiGMGreenspanARupnowMFReduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trialBMC Psychiatry2006614517054789
- KwonJSKimSNHanJSatisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychoticsInt Clin Psychopharmacol201530632032826196188
- NHSPayment by Results Guidance for 2013–142013 Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/232162/Mental_Health_PbR_Guidance_for_2013-14.pdfAccessed May 10, 2017
- VernonMKRevickiDAAwadAGPsychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patientsSchizophr Res20101181–327127820172695
- WHO [webpage on the Internet]WHO International Classification of Diseases2017 Available from: http://www.who.int/classifications/icd/en/Accessed May 10, 2017
- ChuePThe relationship between patient satisfaction and treatment outcomes in schizophreniaJ Psychopharmacol2006206 suppl385617046986
- Capita Business ServicesPayment by Results Data Assurance Framework2013 Available from: http://www.chks.co.uk/userfiles/files/PR/Mental Health PbR July 2013.pdfAccessed May 26, 2017
- MonitorImproving Payment for Mental Health Services2015 Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/492743/Improving_payment_for_mental_health_services_WebinarFAQs_FINAL.pdfAccessed May 26, 2017
- Mental Health Taskforce IThe Five Year Forward View for Mental Health2016 Available from: https://www.england.nhs.uk/wp-content/uploads/2016/02/Mental-Health-Taskforce-FYFV-final.pdfAccessed May 26, 2017